{"name":"AM-Pharma","slug":"am-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Alkaline Phosphatase","genericName":"Alkaline Phosphatase","slug":"alkaline-phosphatase","indication":"Treatment of hypophosphatasia","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"recAP","genericName":"recAP","slug":"recap","indication":"Sepsis-associated organ dysfunction","status":"marketed"}]}],"pipeline":[{"name":"Alkaline Phosphatase","genericName":"Alkaline Phosphatase","slug":"alkaline-phosphatase","phase":"phase_2","mechanism":"Alkaline Phosphatase is an enzyme that breaks down phosphate-containing compounds.","indications":["Treatment of hypophosphatasia"],"catalyst":""},{"name":"recAP","genericName":"recAP","slug":"recap","phase":"marketed","mechanism":"recAP is a recombinant alkaline phosphatase that breaks down lipopolysaccharide (LPS) and other inflammatory mediators to reduce systemic inflammation.","indications":["Sepsis-associated organ dysfunction","Inflammatory bowel disease (Crohn's disease and ulcerative colitis)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPdUM0UEUweE9WVW8zVlNEc3pMLUxZdl9ZRlk1U2N6ZGpKOE5iRG9hakZpOG9ZaWpTX0RkMUR4cjVoeFFaN3JKR1RDcDBrQkktd3RaMGJ6OEJBNjhoOGRubGd1bHRvOHBVSjgzcU4zWnlNdnpLZ0FCaHJpQ01lNG14am5IU2c5NFlDZUU3VHAxUTVGdUowZnJuTVVuZkF6OFNyR0p2Nmdyc3piZW5CTmk1YXV0WTdtMEZxb0V6LW1RWFZXM21xSHF1YkV0dW5HUlR1Y0FsVTIxZkRFWVYxNVJFV256QTIwdUVRZDBGazFJSXVUYVE?oc=5","date":"2026-04-07","type":"regulatory","source":"Whalesbook","summary":"Aurobindo Pharma Gets FDA Approval for Generic Diabetes Drug, Eyes Market Share - Whalesbook","headline":"Aurobindo Pharma Gets FDA Approval for Generic Diabetes Drug, Eyes Market Share","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSDh1T3czekxyeHRJS2l3SWhUbEpvVEtuSl95bnBsd2pyZk53NkVwaUtOQUpIb3VvYnF2R0FqRlEtWlBpeGRmbnZWQ1ZQWFh6Z3R6QlZRSmRUeVlPMUxUVXo1U0gxY1BNYW4wWWMxNDRjSmpFaGo4YmlRSjY1T1JBTUFCZzBOektoM2xnVHVQYTNzZmFGd0lJUTYzRTExRzFsdkxjc3JLSzluWEl6RGZJaEZBcUYxZEFsbjN1NzBBODFnUQ?oc=5","date":"2026-04-02","type":"pipeline","source":"seekingalpha.com","summary":"AM Markets Need to Know: Pharma tariffs soon, Gulf states look to bypass Hormuz, and more (SP500:) - seekingalpha.com","headline":"AM Markets Need to Know: Pharma tariffs soon, Gulf states look to bypass Hormuz, and more (SP500:)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-19","type":"pipeline","source":"Medical Dialogues","summary":"Fake Telma AM Racket Busted in Thane, Two Pharma Distributors Arrested - Medical Dialogues","headline":"Fake Telma AM Racket Busted in Thane, Two Pharma Distributors Arrested","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYXl0RDVaejNwM0xlUklDSE5iUFFVclA2dDJnXzgwazladnhiTFZ6eWd0cG51amliSFlwTHVmX1VRNEVMS3B2NENKUm1BYlRzMGJ3dHczeWFJV2FmZmRKbmJLMDBVSl9jREMtMzA0Q3pHeExLR0p3Sm00cGdLTkdaVHMxZDlLT0pqLTlpaExuem1HLXB1bXQ4dmRNdDV4N0w0cXpybTNwQ1A?oc=5","date":"2026-01-15","type":"pipeline","source":"arstechnica.com","summary":"“I am very annoyed”: Pharma execs blast RFK Jr.’s attack on vaccines - arstechnica.com","headline":"“I am very annoyed”: Pharma execs blast RFK Jr.’s attack on vaccines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNQjlHNlhYNEJqV1ZjWFdaTmFSYjI4di00ZWRyRElWWmNDV3RuSFZGRG1SMWtLRUtkR2R4YU9SbW9QQkIyTWRhZzdQWEdDcXlRU2NLcFRQblExckpXZ3A0eUI4bG5wZkF2NGhKeUlRNFI1aXUzd2VmN0M2Z1d6ZEtzc1ZMbVVZSTNhdzFoSXVKVElVWWZBVlJOV2hIUW4?oc=5","date":"2025-12-03","type":"pipeline","source":"City AM","summary":"Britain is missing out on pharma investment thanks to medicine rationing - City AM","headline":"Britain is missing out on pharma investment thanks to medicine rationing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQRTBad0Z5bzdBRTRLWTVJbnZ0dGhhMnIyMFFkcmYyVVVzV0hiVk1vNV9QcHUydFVHb3hubURIZkptbDlVZVp0WG1UOVZUN2NoXzRralRLZG91bkNfcnpzUGJwS2pRR0t3bjZWQllLVUdZOENyOWp6UFJIRmFnbFRySHpEeV9JdjRzMTE4NDRpYTQxTnJXMFJlODJRZUdPaUVlVm1sb2JWNHFNVmF2OGpjZFNVTFZONFFWNUtjaU9DNUZmbGc5YmdCbkxWcm1BYUI5N1JrUllvUTRnMEFkMHdHMmlqMGNGNjhYdUwzdW9fUkV2R0lrUV92UlhoTEcxODY3c3MtOWZYdGNHRzRPWHExeC14ZlozNFhhSkFqTDhMdFA?oc=5","date":"2025-10-02","type":"trial","source":"GlobeNewswire","summary":"AM-Pharma Completes Enrollment in Phase 2 Study of - GlobeNewswire","headline":"AM-Pharma Completes Enrollment in Phase 2 Study of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBNN0Rhb0lJTll3M3pmQkhqTEVPS1JycC05RTBRcXp6dGpTOG51Rlo5b3oyMDN2cjlpcy0wT3RDb3RkRlJmZ3V6M0trY2hlNmJ6T2pJV3U3R19RSkxtRmJkY0VQU2RJQQ?oc=5","date":"2024-06-30","type":"pipeline","source":"The Pharma Letter","summary":"AM-Pharma - The Pharma Letter","headline":"AM-Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOVGNMYmFzNDdDajRkYVhoX242ai1TRW9wc3I4SUstUHhraDU0ajlCQlBTcnhzeXlIbl9TbzZJVUw0V05wbDNmbTdnRTZ6X2c4OHM1V2szMnVTWWR6a2t5emx1NlBzeHJNT0V1X3JhRlZjeUVMWHhnVm85djBjTXN3dFdB?oc=5","date":"2023-10-12","type":"trial","source":"Clinical Trials Arena","summary":"AM-Pharma reports positive results from trial of hypophosphatasia therapy - Clinical Trials Arena","headline":"AM-Pharma reports positive results from trial of hypophosphatasia therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQUE9tMl85QmF1ejFWY3pyS29XWDg5aDZOcHdaaG51NkoteFI0UEtKSHU0MjFYYW5xbTVpM1RrR2JtRTZtMUZabUg2Mk1aMjdzX2RrZUZ2WmZLemYyUjRKWHRlenFKTmJ5QXlOaXg3YUxjUEl1X1d5ZWlDVjFlV3VTUUozWGVqaVRfbnhBOUxWcWtUR2EwVWNDTjU1V3o2cFF3akFWNENLQkFOU3hfNWJuSA?oc=5","date":"2023-09-26","type":"pipeline","source":"Fierce Biotech","summary":"AM-Pharma cuts staff, says goodbye to CEO as lead kidney injury asset redirected - Fierce Biotech","headline":"AM-Pharma cuts staff, says goodbye to CEO as lead kidney injury asset redirected","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOWTdRUUd0NmhrUUc4c3Z4Tkp6aE5YSWloalA1RW1YVHNkbkFXRHExWVdFZDBkMUR4SEhyNXdOYzdEZ19mUmJJNF9CWTBMSFFRTEpnb0JEbFhmOUNIUF9iSTdEakNVMEtiRHkwUldUdkF6UmR5LTI5eENDRkctMDFUeHpiOTdCeEpHdFhzajVmaDBiWHlYUXJ4a0JKcnNBeTM1TUFsUWZTbXkzRURHczBF?oc=5","date":"2022-10-20","type":"trial","source":"Fierce Biotech","summary":"AM-Pharma, once a Pfizer takeover target, flunks phase 3 kidney injury trial - Fierce Biotech","headline":"AM-Pharma, once a Pfizer takeover target, flunks phase 3 kidney injury trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFB5VmppQ3k2SHktWERuZ1JfbHpsUGQtU1JpbnV4WDhvWXJzMkxfOHZhSEtTTjRpZDdKU01aNU9NNEFCcFlVVkFKbXpfOEpsZkZaNG53anMxVkY3ZVFfZnRxLUdqTnpncWxhUTIxWU5jUTdTWFRyeC1xaU1lZw?oc=5","date":"2021-01-08","type":"trial","source":"Pharmaceutical Business review -","summary":"AM-Pharma enrols first patients in Covid-19 phase III trial - Pharmaceutical Business review -","headline":"AM-Pharma enrols first patients in Covid-19 phase III trial - Pharmaceutical Business review -","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5waW00SXlsaF8xYTNqM2UwWHJNUnpIOVV3aTlZRGZQMVczTHZvbDFXUjBYQm5lb0FOMXVHc3BwNDAxVzZtVjlCUlVMQ0w0NmpQWE5sNTFXdVI2LVQ1bFNQWncwWDFOdVFTY2FMUi1EN2gtMWxmY3c?oc=5","date":"2019-07-16","type":"trial","source":"labiotech.eu","summary":"Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M - labiotech.eu","headline":"Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}